Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.77 |
| ▸ | GAA | P10253 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4772036 | 0.92 | KDM4E (0.90) | MAPTGAAKDM4ELMNASMN1; SMN2 | |
| SCHEMBL7000216 | 0.91 | KDM4E (0.92) | MAPTGAAKDM4ELMNASMN1; SMN2 | |
| SCHEMBL14039394 | 0.82 | L3MBTL1 (0.97) | MBTD1L3MBTL1ALDH1A1SIGMAR1KMT2A | |
| SCHEMBL3327029 | 0.82 | L3MBTL1 (0.72) | MBTD1L3MBTL1SIGMAR1KMT2AHRH3 | |
| SCHEMBL4770184 | 0.82 | L3MBTL1 (0.72) | MAPTGAAKDM4ELMNASMN1; SMN2 | |
| SCHEMBL23682795 | 0.81 | L3MBTL1 (1.00) | MBTD1L3MBTL1ALDH1A1SIGMAR1KMT2A | |
| SCHEMBL3322160 | 0.81 | L3MBTL1 (0.74) | MAPTGAAKDM4ELMNASMN1; SMN2 | |
| SCHEMBL1636286 | 0.81 | L3MBTL1 (0.74) | MAPTGAAKDM4ELMNASMN1; SMN2 | |
| SCHEMBL10854490 | 0.81 | SIGMAR1 (0.83) | MAPTGAAKDM4ELMNASMN1; SMN2 | |
| SCHEMBL6034608 | 0.81 | SIGMAR1 (0.83) | MAPTGAAKDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303496-B9 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1303496-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| US-6908920-B2 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-06-21 | — | — | US | disclosed |
| US-20030216406-A1 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| EP-1303496-A1 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002004429-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216406-A1 | Pyrimidine derivatives | TYMP, TYMS, CCNT1 | MAPT 4272/4885GAA 904/4885KDM4E 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.